Poor UK support for paediatric study incentives

摘要

The UK government is unlikely to back an Irish proposal that there should be transition incentives for drug companies to conduct paediatric studies,in advance of EU legislation requiring them to do so,according to industry insiders.'The issue is that there is a high level of use of unlicensed drugs in children,' said Richard Tiner.medical director at the Association of British Pharmaceutical Industry,London,And unless companies get incentives ahead of the legislation,they are unlikely to do anything about changing that.In the meantime,the sickest children in Europe will continue to be given the wrong dosage of drugs,or potentially harmful drugs developed for use in adults.